Chromosome aberrations as a predictor of clinical outcome for smoking associated lung cancer

Randa El-Zein, Sherif Z. Abdel-Rahman, Nivea Conforti-Froes, Scott K. Alpard, Jospeh B. Zwischenberger

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


The ability to identify individuals at greatest risk of developing lung cancer can significantly enhance the efficacy of intervention modalities. One strategy for identifying these individuals is through biomarkers that reflect the severity of their cancer. In the present study, we evaluated 22 lung cancer patients and 35 controls to determine whether the frequency of chromosome aberrations was significantly associated with specific clinical variables such as the histological type, grade and stage of the tumors. Chromosome aberrations (expressed as total breaks) were investigated on chromosome 1 in interphase nuclei obtained from blood lymphocytes of the study participants using the fluorescence in situ hybridization (FISH) chromosome aberration assay. Our results indicate a significant linear increase (P = 0.01) in the level of breaks with respect to the grade of the carcinoma. The poorly differentiated tumors had a significantly higher level of chromosome breaks mean ± SD (1.7 ± 0.46) as compared to the well differentiated tumors (0.98 ± 0.23, P < 0.05). These results indicate that chromosome aberrations, as determined by the FISH assay, can be used as a biomarker for identifying individuals with aggressive types of lung cancer and potentially, as a predictor for prognostic outcome of the disease. (C) 2000 Elsevier Science Ireland Ltd.

Original languageEnglish (US)
Pages (from-to)65-71
Number of pages7
JournalCancer Letters
Issue number1
StatePublished - Sep 29 2000


  • Chromosome aberrations
  • Fluorescence in situ hybridization
  • Grades
  • Histoplathology
  • Lung cancer
  • Smoking
  • Stages

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Chromosome aberrations as a predictor of clinical outcome for smoking associated lung cancer'. Together they form a unique fingerprint.

Cite this